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Abstract
Objective
To study the relationship between endothelial dysfunction, HIV infection, and stroke in
Malawians.
Methods
Using a cross-sectional design, we measured plasma levels of intercellular adhesion molecule-1
(ICAM-1), plasminogen activator inhibitor-1 (PAI-1), vascular endothelial growth factor
(VEGF), and soluble thrombomodulin (sTM) in stroke patients and controls, stratiﬁed by HIV
status. These biomarkers were measured using ELISA. After dichotomization, each biomarker
was used as the dependent variable in a multivariable logistic regression model. Primary
independent variables included HIV and stroke status. Adjustment variables were age, sex,
hypertension, diabetes mellitus, tobacco and alcohol consumption, personal/family history of
stroke, antiretroviral therapy status, and hypercholesterolemia.
Results
Sixty-one stroke cases (19 HIV+) and 168 controls (32 HIV+) were enrolled. The median age
was 55 years (38.5–65.0) for controls and 52 years (38.0–73.0) for cases (p = 0.38). The
median CD4+ T-cell count was 260.1 cells/mm3 (156.3–363.9) and 452 cells/mm3
(378.1–527.4) in HIV-infected cases and controls, respectively. HIV infection was in-
dependently associated with high levels of ICAM-1 (OR = 3.6, 95% CI: 1.3–10.6, p = 0.018) in
controls but not in stroke cases even after excluding patients with a viral load >1,000 RNA
copies/mL (OR = 4.1, 95% CI: 1.3–13.1, p = 0.017). There was no association between the
clinical proﬁles of HIV-positive controls or HIV-positive stroke and high levels of PAI-1, VEGF,
and sTM.
Conclusions
HIV infection is associated with endothelial activation despite antiretroviral treatment. Our
ﬁndings underscore the need for larger clinical cohorts to better understand the contribution of
this perturbation of the endothelial function to the increasing burden of cardiovascular diseases
in sub-Saharan Africa.
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The vascular endothelium is a critical regulator of cell adhesion,
inﬂammation, coagulation, and vascular remodeling. Pertur-
bation of one or more of these functions, also known as en-
dothelial dysfunction, is induced by classical cardiovascular risk
factors. Endothelial dysfunction is a major component of local
and systemic inﬂammation. At the early stage of endothelial
activation, there is increased expression of cell adhesion mol-
ecules (e.g., intercellular adhesion molecule-1 [ICAM-1]) on
the surface of endothelial cells to facilitate leukocyte trans-
endothelial migration. The occurrence of endothelial damage
leads to the secretion of other biomarkers, notably plasminogen
activator inhibitor-1 (PAI-1) and soluble thrombomodulin
(sTM) responsible for the perturbation of the coagulation
process and vascular endothelial growth factor (VEGF) re-
sponsible for angiogenesis.1 The interaction of these bio-
markers with other proinﬂammatory cytokines, as well as white
blood cells and smooth muscle cells, leads to vessel wall
remodeling and ultimately to various types of vasculopathy.
Several studies conducted on HIV populations from Western
countries have reported an association between high levels of
biomarkers of endothelial dysfunction and death and/or
cardiovascular endpoints.2 However, it is unknown whether
the same association is observed in a sub-Saharan African
setting, where antiretroviral therapy (ART) has become more
widespread. This knowledge gap provides the rationale for
this study conducted to evaluate the relationship between
endothelial dysfunction, HIV infection, and stroke in Malawi.
Methods
Standard protocol approvals, registrations,
and patient consents
This work was conducted as part of the study of Biomarkers of
Stroke and Arterial Diseases in Malawian Adults, which was
approved by the Research Ethics Committees of the Liver-
pool School of Tropical Medicine and the University of
Malawi College of Medicine. The study used plasma samples
available in the biobank of the Malawi START study, a case-
control study designed to identify risk factors of stroke in
Malawi, where the prevalence of HIV infection is 10.3%.3 All
patients enrolled in the Malawi START study provided
a written informed consent that allowed their blood speci-
mens to be reused for subsequent ethically cleared studies
within a 5-year period from the time of collection.
Patient selection
As previously described,3 stroke cases enrolled in the original
Malawi START study were adult residents of Blantyre pre-
senting at the Queen Elizabeth Central Hospital within 7 days of
symptom onset, meeting theWHO’s clinical deﬁnition of stroke,
and having a brain MRI conﬁrming the diagnosis. Two com-
munity controls were selected for each case with the goal of
obtaining an age/sex frequency-matched random sample of the
population, with a geographical distribution in proportion to the
population density. The subsequent patient selection (or more
accurately “plasma specimen selection”) for the current study is
described in ﬁgure.
Demographic and clinical data of cases and controls included
age, sex, hypertension, diabetes status, tobacco and alcohol
consumption status, personal/family history of stroke, CD4+
T-cell count, HIV viral load, hypercholesterolemia, ART
status, recent infection, and National Institute of Health
Stroke Score for stroke cases only.3 The stroke type and eti-
ology were deﬁned using MRI brain imaging and the trial of
Org 10172 in acute stroke treatment criteria, respectively.3
Selection of biomarkers of
endothelial dysfunction
The biomarkers measured in this study were selected to assess
the diﬀerent stages of endothelial dysfunction as described in
Figure Flow diagram of case and control selection
Glossary
ART = antiretroviral therapy; CV = coeﬃcient of variability; ICAM = intercellular adhesion molecule; IQR = interquartile
range; PAI = plasminogen activator inhibitor; sTM = soluble thrombomodulin; VEGF = vascular endothelial growth factor.
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the introduction. Themajor cellular source of ICAM-1, PAI-1,
and thrombomodulin is activated endothelial cells.4 VEGF, an
essential growth factor for endothelial cells, is produced by
macrophages, platelets, and keratinocytes. There is no vali-
dated normal range for the plasma concentration of bio-
markers of endothelial dysfunction. Higher concentrations
correlate well with the magnitude of local or systemic in-
ﬂammation and have been consistently associated with an
increased cardiovascular risk. Because HIV-infected individ-
uals have persistent systemic inﬂammation,5 we hypothesized
that they would have higher levels of biomarkers of endo-
thelial dysfunction, explaining their greater risk of stroke.
Measurement of biomarkers of
endothelial dysfunction
The plasma concentrations of ICAM-1, PAI-1, VEGF, and
sTM were measured using ELISA kits (Abcam, Cambridge,
United Kingdom). SimpleStep ELISA kits were used for
ICAM-1, PAI-1, and sTM, whereas the standard kit was used
for VEGF. All samples were run in duplicates. Samples with an
individual coeﬃcient of variability (CV) greater than 25%
were reanalyzed.
All the ELISA tests were performed according to the manu-
facturer’s instructions with the exception of the washing steps
that were performed with an automated washer (Wellwash;
ThermoFisher Scientiﬁc, Waltham, MA) using a mixture of
Tween 20 and phosphate-buﬀered saline (0.05% vol/vol).
The plates were read at 450 nm using an automated micro-
plate reader (Multiskan; ThermoFisher Scientiﬁc). The
standard curves were constructed using a 4-parameter logistic
regression ﬁtting equation (online software: elisaanalysis.
com). The mean intra-assay and inter-assay CV for ICAM-1,
PAI-1, and VEGF was <10% and <15%, respectively.
Statistical analysis
The statistical analyses were performed using the software
STATA (version 13; StataCorp, College Station, TX). Based
on the stroke and HIV status, 4 clinical proﬁles were deﬁned:
HIV-negative controls, HIV-positive controls, HIV-negative
stroke, and HIV-positive stroke. Demographic and clinical
parameters were summarized as proportions for categorical
variables and median with interquartile range (IQR) for nu-
merical variables. For comparisons across groups, Fisher exact
and Kruskall-Wallis tests were used for categorical and nu-
merical variables, respectively.
The third tertile of the distribution of plasma concentration
values was considered as the threshold for the distinction
between high and low levels for each biomarker. To identify
the predictors of endothelial dysfunction, the plasma level of
each biomarker was included as a binary dependent variable
(low/high levels) in a separate multivariable logistic re-
gression analysis. Age, sex, hypertension, diabetes mellitus,
tobacco and alcohol consumption, personal/family history of
stroke, ART status, and hypercholesterolemia were included
in the model as potential confounders. We also explored the
plasma levels of the biomarkers as a continuous variable in
a separate multiple linear regression analysis.
To further explore the eﬀect of ART, the regression analyses
described above were repeated after excluding HIV-positive
patients with a viral load greater than 1,000 RNA copies/mL
(25 of 48 HIV-positive participants with viral load available).
The cutoﬀ thresholds to distinguish between high and low
levels of biomarkers were recalculated to adjust for the change
in the population structure and size. The ART status was not
included as a confounder in multivariable analyses because
87% of patients with a low or undetectable viral load were
on ART.
All the statistical tests performed were 2-tailed, and statistical
signiﬁcance was deﬁned as p < 0.05.
Data availability
The database of the Malawi START study is available for
consultation or reuse on request to the principal investigator
(L.B.). Sharing of all or part of this database is subject to prior
authorization by the University of Malawi College of Medi-
cine Research Ethics Committee.
Results
Participants’ characteristics
The 229 participants (50.2% women) included in this study
were distributed as follows: 136 HIV-negative controls, 32
HIV-positive controls, 42 HIV-negative cases, and 19 HIV-
positive cases. Themedian age of the participants was 55 years
(IQR: 38.0–65.0). Participants’ baseline characteristics are
summarized in table 1.
The etiologies of 60 of 61 ischemic strokes were as follows: 7
(12%) atherosclerotic strokes, 5 (8%) cardio-thromboembolic
strokes, 16 (27%) strokes with other determined causes, and 32
(53%) strokes with an undetermined cause.
Factors associated with
endothelial dysfunction
In the logistic regression analysis, the adjusted OR for having
high plasma levels of ICAM-1 was 3.6 (95% CI: 1.3–10.6, p =
0.018) for the proﬁle “HIV-positive controls” and 1.2 (95%
CI: 0.4–4.0, p = 0.772) for the proﬁle “HIV-positive stroke”
(table 2). The adjusted OR for having high plasma levels of
PAI-1, sTM, or VEGF was not signiﬁcant for HIV-positive
controls and HIV-positive stroke. The adjusted OR for having
high plasma levels of PAI-1 was 0.4 (95% CI: 0.1–0.9, p =
0.037) for the proﬁle “HIV-negative stroke” (table 2). Linear
regression did not modify the associations reported here.
After excluding HIV-positive patients with a viral load greater
than 1,000 RNA copies/mL, the adjusted OR for having high
plasma levels of ICAM-1 was 4.1 (95% CI: 1.3–13.1, p =
0.017) for the proﬁle “HIV-positive controls,” whereas the
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OR for having high plasma levels of PAI-1 was 0.5 (95% CI:
0.2–1.3, p = 0.183).
Discussion
Our results show that HIV infection is independently asso-
ciated with high plasma levels of ICAM-1, a biomarker of
endothelial activation. There was no association between
stroke status and high levels of ICAM-1 or between HIV
infection and high levels of PAI-1, sTM, and VEGF (table e-1,
links.lww.com/NXI/A94).
The association betweenHIV infection and high levels of ICAM-
1 reported here expands the limited literature on sub-Saharan
Africa6 and is consistent with ﬁndings from high-income coun-
tries.2 Although other risk factors, such as diabetes, hypercho-
lesterolemia, and ART, can contribute to endothelial activation,
we found that this association is independent of those factors.
Chronic systemic inﬂammation induced by HIV infection is
a trigger for endothelial activation,7 which is an important
component of endothelial dysfunction. In turn, endothelial
activation and dysfunction are both risk factors for atherogenesis.
For example, high levels of ICAM-1 have been associated with
increasing carotid intima-media thickness, a surrogate marker of
atherosclerosis and a predictor of cardiovascular events.2,8 In our
cohort, more than 50% of the HIV-positive controls were on
ART, and their CD4+ T-cell count was >400 cells/mm3. This
means that despite having a relatively stable infection, HIV-
infected individuals still have an ongoing endothelial activation as
demonstrated by previous studies conducted in Western coun-
tries.9 Therefore, ART alone might not be enough to suppress
cardiovascular risk in people living with HIV, and additional
interventions to control HIV-related inﬂammation might be
needed. One potential interventionmight be the use of statins as
an adjunct therapy to attenuate endothelial dysfunction and
vascular inﬂammation.
Unexpectedly, we showed no association between HIV and
endothelial dysfunction among patients with stroke. The most
likely explanation is that our sample size was too small, with
only 19 HIV-positive stroke cases. Furthermore, despite
restricting the analysis to ischemic stroke, the cohort remained
Table 1 Demographic and clinical characteristics of study participants
Controls Ischemic stroke cases
Total
(n = 229) p-Value
HIV negative
(n = 136)
HIV positive
(n = 32)
HIV negative
(n = 42)
HIV positive
(n = 19)
Women, n (%) 72 (52.9) 12 (37.5) 21 (50.0) 10 (52.6) 115 (50.2) 0.47
Age (y), median, IQR 58.0
(43.0–65.0)
47.5 (36.5–60.0) 63 (44.0–77.0) 42 (30.0–52.0) 55 (38.0–65.0) 0.001
Hypertension, n (%) 77 (56.6) 11 (34.4) 38 (90.5) 12 (63.2) 138 (60.3) <0.001
Diabetes mellitus, n (%) 2 (1.5) 1 (3.1) 5 (11.9) 0 (0.0) 8 (3.5) 0.02
Tobacco consumption, n (%) 15 (11.0) 7 (21.9) 11 (26.2) 1 (5.3) 34 (14.9) 0.04
Alcohol consumption, n (%) 26 (19.1) 9 (28.1) 8 (19.1) 2 (10.5) 45 (19.7) 0.50
Previous stroke, n (%) 4 (2.9) 0 (0.0) 2 (4.8) 0 (0.0) 6 (2.6) 0.82
Family history of stroke, n (%) 12 (8.8) 3 (9.4) 6 (14.3) 3 (15.8) 24 (10.5) 0.58
CD4 count (cell/mm3),
Mean, 95% CI
— 452.7 (378.1–527.4) — 260.1 (156.3–363.9) 379.0 (314.3–443.6) 0.002a
Total cholesterol (mmol/L) 3.9 (2.8–4.6) 3.6 (2.3–4.7) 3.4 (2.9–4.0) 3.3 (2.3–4.1) 3.6 (2.6–4.5) 0.63
Viral load (RNA copies/mL),
median, IQR
— 1,836.0
(1.0–68,416.0)
— 1,883.5
(1.0–35,793.0)
1,883.5
(1.0–57,596.0)
0.80a
Viral load >1,000
RNA copies/mL, n (%)c
— 15 (50.0) — 10 (55.6) 25 (52.1) 0.71a
On ART, n (%) — 17 (53.1) — 9 (47.4) 26 (51.0)d 0.45a
NIHSS—median, IQR — — 13.5
(8.0–18.0)
12.0 (9.0–14.0) 13.0 (8.0–17.0) 0.56b
Abbreviation: IQR = interquartile range.
The median age was 55 years (38.5–65.0) for controls and 52 years for cases (38.0–73.0), p = 0.38.
The CD4 count was available for 29 HIV-positive controls and 18 HIV-positive cases.
a p Value displayed only for comparison between HIV-positive controls and cases.
b p Value displayed only for comparison between HIV-negative and HIV-positive cases.
c The HIV viral load was available for 30 HIV-positive controls and 18 HIV-positive cases (3 missing values).
d The denominator for the percentage displayed is 51 (total number of HIV-positive participants).
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heterogeneous, thus reducing our statistical power further and
our ability to explore the varied etiologies of cerebrovascular
diseases. However, the independent association between HIV
infection and high levels of ICAM-1 in the control group
suggests that a cardiovascular risk does exist. Consequently,
further evaluation in a larger clinical cohort is warranted.
PAI-1 is amolecule that inhibits ﬁbrinolysis. High and low plasma
levels are expected in ischemic stroke and hemorrhagic stroke,
respectively. A decrease in the plasma concentration of PAI-1
with increasing age has been described.10 Therefore, we suspect
that the association between levels of PAI-I and the proﬁle “HIV-
negative stroke” is due to a residual confounding eﬀect of age.
The absence of a ﬁxed cutoﬀ to distinguish between low
and high plasma levels of the biomarkers considered in this
study represents a limitation and continues to be a challenge
in this ﬁeld. However, there is good evidence that high
plasma concentrations are related to increased cardiovascular
risk.2,11,12
Overall, this study conﬁrms the association between HIV
infection and endothelial activation despite ART in a sub-
Saharan African setting. Larger well-phenotyped cohort
studies are needed to clarify the contribution of HIV-related
endothelial activation to the long-term stroke morbidity and
mortality in the ART era.
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Table 2 Univariable and multivariable analyses of factors associated with high levels of biomarkers of endothelial
dysfunction
Biomarkers of endothelial dysfunction
and participants’ clinical profilea
No. of participants with a high
plasma level of the biomarker (%)
Univariable model Multivariable modelb
Crude
OR 95% CI
p-
Value
Adjusted
OR 95% CI
p-
Value
ICAM-1
HIV-negative controls 36 (26.5) 1 1
HIV-positive controls 21 (65.6) 5.3 2.3–12.1 <0.001 3.6 1.3–10.6 0.018
HIV-negative stroke 12 (28.6) 1.1 0.5–2.4 0.789 1.0 0.4–2.4 0.978
HIV-positive stroke 7 (36.8) 1.6 0.6–4.4 0.348 1.2 0.4–4.0 0.772
PAI-1
HIV-negative controls 50 (36.76) 1 1
HIV-positive controls 11 (34.4) 0.9 0.4–2.0 0.800 0.6 0.2–1.7 0.303
HIV-negative stroke 9 (21.4) 0.5 0.2–1.1 0.069 0.4 0.1–0.9 0.037
HIV-positive stroke 6 (31.6) 0.8 0.3–2.1 0.660 0.6 0.2–2.0 0.397
sTM
HIV-negative controls 49 (36.0) 1 1
HIV-positive controls 7 (21.9) 0.5 0.2–1.3 0.132 0.3 0.1–1.2 0.084
HIV-negative stroke 18 (42.9) 1.3 0.7–2.3 0.425 1.8 0.8–4.3 0.131
HIV-positive stroke 2 (10.5) 0.2 0.1–1.2 0.042 0.2 0.0–1.0 0.050
VEGF
HIV-negative controls 45 (33.1) 1 1
HIV-positive controls 11 (34.4) 1.1 0.5–2.4 0.890 0.9 0.3–2.7 0.830
HIV-negative stroke 12 (28.6) 0.8 0.4–1.7 0.584 0.8 0.3–1.8 0.599
HIV-positive stroke 8 (42.1) 1.5 0.6–3.9 0.440 1.4 0.4–4.8 0.556
Abbreviations: ART = antiretroviral therapy; ICAM = intercellular adhesion molecule; PAI = plasminogen activator inhibitor; sTM = soluble thrombomodulin;
VEGF = vascular endothelial growth factor.
a Number of participants belonging to each clinical profile: HIV-negative controls (n = 136), HIV-positive controls (n = 32), HIV-negative stroke (n = 42), and HIV-
positive stroke (n = 19). Only cases with ischemic stroke were included.
b Adjustment variables were age, sex, hypertension, diabetes mellitus, tobacco and alcohol consumption, ART status, hypercholesterolemia, and recent
infection. None of these variables had an OR significantly higher than 1. The variable “personal and family history of stroke” was omitted because of
collinearity.
Neurology.org/NN Neurology: Neuroimmunology & Neuroinflammation | Volume 6, Number 2 | March 2019 5
laboratory analyses under the supervision of J. Flatley and M.
Griﬃths. J. Kamtchum-Tatuene performed the statistical
analyses under the supervision of L. Benjamin and H.
Mwandumba. J. Kamtchum-Tatuene drafted the ﬁrst version
of the manuscript that was edited by L. Benjamin. H.
Mwandumba, Z. Al-Bayati, J. Flatley, M. Griﬃths, and T.
Solomon revised the subsequent versions of the manuscript.
All authors approved the ﬁnal version.
Acknowledgment
The authors are grateful to (1) all the patients and their
families for consenting to take part in this study, (2) the staﬀ
of the Institute of Infection and Global Health and the
Wellcome Trust Centre for Global Health Research for their
administrative support, and (3) the staﬀ at Malawi-Liverpool-
Wellcome Clinical Research Programme and Queen Eliz-
abeth Central Hospital.
Study funding
This research was funded by theWellcome Trust [106829/Z/
15/Z to JKT and CNR11146 to L.B.]. L.B. was also supported
by an NIHR Clinical Lectureship.
Disclosure
J. Kamtchum-Tatuene received research support from Ge-
neva University Hospital Fund for Research and De-
velopment and theWellcome Trust. H.Mwandumba received
research support from the Bill andMelinda Gates Foundation
and MRC. Z. AL-Bayati and J. Flatley report no disclosures.
M. Griﬃths received travel funding from British Paediatric
Neurology Association and Royal College of Physicians of
Edinburgh; received research support from Fast Track Diag-
nostics Research Limited, Department of Health UK NIHR,
MRC, European Commission, Ministry of France, and Re-
public of Indonesia. T. Solomon served on a commercial data
safety monitoring board for the study of Ebola vaccine; served
on a clinical advisory board of Siemens Healthineers; received
travel funding fromWorld Congress of Neurology, South East
Asia Encephalitis, European Commission, and WHO; and
received research support from NIHR HPRU. L. Benjamin
received research support from GlaxoSmithKline. Full dis-
closure form information provided by the authors is available
with the full text of this article at Neurology.org/NN.
Publication history
Received by Neurology: Neuroimmunology & Neuroinﬂammation July 2,
2018. Accepted in ﬁnal form October 16, 2018.
References
1. Benjamin LA, Bryer A, Emsley HC, Khoo S, Solomon T, Connor MD. HIV infection
and stroke: current perspectives and future directions. Lancet Neurol 2012;11:
878–890.
2. Ross AC, Rizk N, O’Riordan MA, et al. Relationship between inﬂammatory markers,
endothelial activation markers, and carotid intima-media thickness in HIV-infected
patients receiving antiretroviral therapy. Clin Infect Dis 2009;49:1119–1127.
3. Benjamin LA, Corbett EL, Connor MD, et al. HIV, antiretroviral treatment, hyper-
tension, and stroke in Malawian adults: a case-control study. Neurology 2016;86:
324–333.
4. Zhang J, Defelice AF, Hanig JP, Colatsky T. Biomarkers of endothelial cell activation
serve as potential surrogate markers for drug-induced vascular injury. Toxicol Pathol
2010;38:856–871.
5. Sereti I, Krebs SJ, Phanuphak N, et al. Persistent, albeit reduced, chronic inﬂammation
in persons starting antiretroviral therapy in acute HIV infection. Clin Infect Dis 2017;
64:124–131.
6. Graham SM, Rajwans N, Jaoko W, et al. Endothelial activation biomarkers increase
after HIV-1 acquisition: plasma vascular cell adhesion molecule-1 predicts disease
progression. AIDS 2013;27:1803–1813.
7. Melendez MM, McNurlan MA, Mynarcik DC, Khan S, Gelato MC. Endothelial
adhesion molecules are associated with inﬂammation in subjects with HIV disease.
Clin Infect Dis 2008;46:775–780.
8. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical car-
diovascular events with carotid intima-media thickness: a systematic review and meta-
analysis. Circulation 2007;115:459–467.
9. de Larrañaga GF, Bocassi AR, Puga LM, Alonso BS, Benetucci JA. Endothelial
markers and HIV infection in the era of highly active antiretroviral treatment. Thromb
Res 2003;110:93–98.
10. Surjawan Y, Setiabudy RD, Suryaatmadja M, Ranakusuma TAS. The association of
plasminogen activator inhibitor-1 level with ischemic stroke (preliminary study). Med
J Indones 2009;19:158–163.
11. Knudsen A, Katzenstein TL, Benﬁeld T, et al. Plasma plasminogen activator inhibitor-1
predicts myocardial infarction in HIV-1-infected individuals. AIDS 2014;28:1171–1179.
12. Musselwhite LW, Sheikh V, Norton TD, et al. Markers of endothelial dysfunction,
coagulation and tissue ﬁbrosis independently predict venous thromboembolism in
HIV. AIDS 2011;25:787–795.
6 Neurology: Neuroimmunology & Neuroinflammation | Volume 6, Number 2 | March 2019 Neurology.org/NN
DOI 10.1212/NXI.0000000000000531
2019;6; Neurol Neuroimmunol Neuroinflamm 
Joseph Kamtchum-Tatuene, Henry Mwandumba, Zaid Al-Bayati, et al. 
setting
HIV is associated with endothelial activation despite ART, in a sub-Saharan African
This information is current as of December 21, 2018
Services
Updated Information &
 http://nn.neurology.org/content/6/2/e531.full.html
including high resolution figures, can be found at:
References
 http://nn.neurology.org/content/6/2/e531.full.html##ref-list-1
This article cites 12 articles, 1 of which you can access for free at: 
Subspecialty Collections
 http://nn.neurology.org//cgi/collection/hiv
HIV
 http://nn.neurology.org//cgi/collection/case_control_studies
Case control studies
 oke
http://nn.neurology.org//cgi/collection/all_cerebrovascular_disease_str
All Cerebrovascular disease/Stroke
following collection(s): 
This article, along with others on similar topics, appears in the
  
Permissions & Licensing
 http://nn.neurology.org/misc/about.xhtml#permissions
its entirety can be found online at:
Information about reproducing this article in parts (figures,tables) or in
  
Reprints
 http://nn.neurology.org/misc/addir.xhtml#reprintsus
Information about ordering reprints can be found online:
Academy of Neurology.. All rights reserved. Online ISSN: 2332-7812.
Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American
Published since April 2014, it is an open-access, online-only, continuous publication journal. Copyright 
is an official journal of the American Academy of Neurology.Neurol Neuroimmunol Neuroinflamm 
